Target-Oriented Approach to Diagnosis and Pharmacotherapy of Nash, a Dialogue Between Academia and Industry
Тези до: 08.09.2017
Дати: 09.11.17 — 11.11.17
Е-мейл Оргкомітету: firstname.lastname@example.org
We would like to cordially invite you to the First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit: Target-oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry’ to be held from 9-11 November 2017 in Rome, Italy.
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed.
This summit will cover both the basic and translational/clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.
Веб-сторінка конференції: https://www.easl.eu/discover/events/detail/2017/first-easl-nafld-summit-target-oriented-approach-to-diagnosis-and-pharmacotherapy-of-nash-a-dialogue-between-academia-and-industry
Конференції по темі - із близькими дедлайнами:
World Infectious Diseases & Rare Diseases CongressТези приймаються до 28.09.19, Budapest